Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and
development of best-in-class oligonucleotides therapeutics. With its AI-empowered
oligonucleotide discovery and development platform, OligoCreator, which integrates a variety
of delivery technologies, Secarna identifies and characterizes oligonucleotide therapeutics
with unparalleled speed and excellent safety and efficacy. By delivering these novel
therapeutics to cells, organs or tissues where they are needed, targeted oligonucleotide
therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat
disorders, profoundly changing the future of medicine.
Secarna Pharmaceuticals at a glance:
| Field of Activity | Secarna has several oligonucleotide drug candidates in immune-oncology, inflammation and fibrosis. |
| Ownership Structure and Financing | Privately held. Secarna generates revenues from technology access fees, R&D funding, license fees, and milestone payments. |
| Product/Services | Lead program SECN-15 is a potential first-in-class antisense oligonucleotide (ASO) targeting Neuropilin 1 (NRP1). Secarna is currently progressing the program towards IND-enabling studies. |
| Unique Selling Point | Secarna’s proprietary AI-empowered drug discovery platform, OligoCreator, combines proven delivery technologies such as antibodies, peptides and carbohydrates with the precision and specificity of oligonucleotides. |
| Partners | Secarna is partner of choice for oligonucleotide development programs with ongoing collaborations with pharma, biotech and academia. Partners include: Lipigon Pharmaceuticals, Evotec, Denali Therapeutics. |
Contact:
 CEO |
 CEO |
| Address | Am Klopferspitz 19 82152 Planegg/Martinsried |
| Telephone | +49 89 215 46 375 |
| info@secarna.com | |
| Web-Address | www.secarna.com |
| Social Media | |
| Date of Incorporation/ Number of Employees |
2015/ 20 |